Stock AnalizStryker Corp. SYK
Medical/Dental Instruments · data as of November 13, 2026
Stryker Corp. (SYK) is a healthcare company listed in the US with a market value of about $117.9B. In the twelve months to September 30, 2026 it had revenue of $26.3B and net income of $3.6B, a net margin of 13.8%.
Its overall Stock Analiz score is 2.8 out of 5 (average). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a P/E of 33.0, a price to free cash flow of 25.8, 5-year revenue growth of 12% a year, a 5-year average ROIC of 9%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 38% below the current price.
Score: 2.8 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- Profitable 5 years in a row
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 5-year average ROIC above 12%
- ROE above 15%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $26.3B | $25.1B | $22.6B | $20.5B | $18.4B | $17.1B | $14.4B | $14.9B | $13.6B | $12.4B | $11.3B |
| Net income | $3.6B | $3.2B | $3.0B | $3.2B | $2.4B | $2.0B | $1.6B | $2.1B | $3.6B | $1.0B | $1.6B |
| Free cash flow | $4.6B | $4.3B | $3.5B | $3.1B | $2.0B | $2.7B | $2.8B | $1.5B | $2.0B | $961M | $1.4B |
| EPS (diluted) | $9.39 | $8.40 | $7.76 | $8.25 | $6.17 | $5.21 | $4.20 | $5.48 | $9.34 | $2.68 | $4.35 |
| Net margin | 13.8% | 12.9% | 13.2% | 15.4% | 12.8% | 11.7% | 11.1% | 14.0% | 26.1% | 8.2% | 14.5% |
| ROIC | — | 9.1% | 9.1% | 10.4% | 8.3% | 8.1% | 6.6% | 9.1% | 9.3% | 10.6% | 11.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 27 analysts is $339.37, 10% above the current price; targets range from $275.00 to $410.00; the consensus rating is “Buy”; expected EPS is $14.83 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Stryker’s P/E ratio?
About 33.0, based on the last twelve months of diluted earnings per share (forward P/E about 18.9).
Is Stryker stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 38% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Stryker pay a dividend?
Yes. The dividend yield is about 1.14%, and it has paid dividends for 10 years in our data.
Is Stryker a good stock to buy?
We do not give buy or sell advice. Stryker scores 2.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.